Navigation Links
Breast Cancer Funding To Be Extended By Another $30 Million: Pharmac

It has been proposed by Pharmac, to hold a meeting regarding extension of funding for the cancer drug Herceptin that would allow the provision of drug to women with early breast cancer. // Currently, funding can only be availed by patients with advanced breast cancer. Extension of the budget for the cancer from the existing $47 million to $77 million has been planned.

The company officials are much more bothered about the safety and efficacy of the anti-cancer drug that is being assessed, according to Dr Peter Moodie, Medical Director, Pharmac. He further stated that the company officials are being open minded about the issue and are really interested in the drug.

The authorization body, Medsafe is yet to approve the proposal of the Pharmac's Pharmacology Therapeutics Advisory Committee.

HER2 positive cancers, an aggressive form account for 30% of all breast cancers against which Herceptin has been shown to be effective. Although previous studies have been able to demonstrate a 46% improved survival rate in those who received the drug and a decreased recurrence rate, the cost constraint has limited widespread use of drug.

Libby Burgess, Chairwoman, Breast Cancer Advocacy Coalition is very hopeful that a lot of valuable lives can be saved by the investment. Most women in New Zealand face severe financial constraints to enable breast cancer treatment. In fact, some even go to the extent of mortgaging their house. Nearly 2500 women in New Zealand are being diagnosed with breast cancer every year.

Pharmac and Roche Products are locally supplying the anti-cancer drug in New Zealand. The pharmaceutical companies are closely working together to extend the available funding. A spokesman for Roche announced that the assessment process is being fast-tracked.


'"/>




Page: 1

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that ... Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains ... lens flare and light leak transitions have a very high-dynamic range for super smooth ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare Products ... was featured in a study indicating superior performance against competitive products in secretion ... Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, ... device company specializing in the treatment of non-melanoma ... keloids, with superficial radiation therapy, today announced that ... year 2016 financial results on Thursday, February 2, 2017 ... will hold a conference call with the investment ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology: